NuView, Otsuka Pharmaceutical deal

NuView granted Otsuka exclusive, worldwide rights to develop and commercialize NuView's genomic-based vasoactive intestinal peptide receptor 1 (VPAC1) diagnostic biomarker to detect prostate and breast cancer. The deal also covers all future diagnostic imaging applications. Otsuka will provide funding for all future clinical trials and commercialization, and will use NuView's US Radiopharmaceuticals Inc. subsidiary to manufacture the diagnostic biomarker. The partners plan to develop the biomarker as a VPAC1-specific radiopharmaceutical for PET imaging procedures. The partners plan to begin a Phase I trial "in the coming months." The partners could not be reached for details. ...